Biotechnology

Cellectis

$33.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-0.48%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can watch Cellectis and buy or sell other stocks, options, and ETFs commission-free!

About CLLS

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France. The listed name for CLLS is Cellectis S.A. American Depositary Shares.

CEO
André Choulika
Employees
264
Headquarters
Paris, Ile-de-France
Founded
1999
Market Cap
1.40B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
488.01K
High Today
$34.71
Low Today
$33.10
Open Price
$33.28
Volume
619.30K
52 Week High
$34.71
52 Week Low
$7.32

Collections

CLLS Earnings

-$0.80
-$0.34
$0.11
$0.57
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 3, After Hours

You May Also Like

SM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure